Express Scripts has announced plans to drop branded Humira from formularies in the US next year, in favor of biosimilar adalimumab rivals. The move comes after a similar decision from fellow pharmacy benefit manager CVS Caremark earlier this year, which has already boosted biosimilars significantly.

The first approved NASH drug topped revenue expectations during its initial quarter on the market, but Madrigal’s share price declined by 12%.

The House Oversight Committee held its third hearing on pharmacy benefit manager reforms in 14 months, but could not elicit an admission from executives that they are responsible for increasing drug prices.

The well-known businessman and TV personality told the White House that the US needs to ‘stop doing business with the big three PBMs,’ helping to fight the drug industry’s battle against the middlemen with a friendlier face not associated directly with the brand industry.